Evolus, Inc. EOLS
Institutional shares held
47 Million
720K
calls
532K
puts
Total value of holdings
$588M
$9.01M
calls
$6.65M
puts
Market Cap
$702M
56,094,800
Shares Out.
Institutional ownership
83.85%
# of Institutions
173
We take great care to ensure that the data presented and summarized in this overview for Evolus, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EOLS
View all-
Perceptive Advisors LLC New York, NY5.75MShares$72 Million1.69% of portfolio
-
Tang Capital Management LLC San Diego, CA4.15MShares$51.9 Million7.07% of portfolio
-
Black Rock Inc. New York, NY3.26MShares$40.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.04MShares$38.1 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.91MShares$36.4 Million2.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.91MShares$36.3 Million0.0% of portfolio
-
Stonepine Capital Management, LLC Bend, OR2.67MShares$33.5 Million29.7% of portfolio
-
Great Point Partners LLC Greenwich, CT2.45MShares$30.6 Million8.39% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.54MShares$19.3 Million0.01% of portfolio
-
State Street Corp Boston, MA1.03MShares$12.9 Million0.0% of portfolio
Latest Institutional Activity in EOLS
Top Purchases
Top Sells
About EOLS
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Insider Transactions at EOLS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 06
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
175,940
-24.81%
|
$2,111,280
$12.59 P/Share
|
|
Jun 06
2024
|
David Moatazedi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
175,940
+19.88%
|
$1,231,580
$7.28 P/Share
|
|
Jun 05
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
155,278
-22.55%
|
$1,863,336
$12.92 P/Share
|
|
Jun 05
2024
|
David Moatazedi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
155,278
+18.4%
|
$776,390
$5.46 P/Share
|
|
Jun 04
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
140,214
-20.82%
|
$1,682,568
$12.73 P/Share
|
|
Jun 03
2024
|
Vikram Malik Director |
SELL
Open market or private sale
|
Direct |
7,500
-2.95%
|
$90,000
$12.96 P/Share
|
|
May 14
2024
|
David N Gill Director |
SELL
Open market or private sale
|
Direct |
6,718
-16.51%
|
$80,616
$12.6 P/Share
|
|
May 13
2024
|
Vikram Malik Director |
SELL
Open market or private sale
|
Direct |
28,000
-9.93%
|
$336,000
$12.93 P/Share
|
|
May 13
2024
|
David N Gill Director |
SELL
Open market or private sale
|
Direct |
3,643
-8.22%
|
$43,716
$12.72 P/Share
|
|
May 10
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,423
-1.57%
|
$29,076
$12.72 P/Share
|
|
May 10
2024
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
3,441
-0.92%
|
$41,292
$12.72 P/Share
|
|
May 10
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
16,051
-2.33%
|
$192,612
$12.72 P/Share
|
|
Mar 27
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
6,236
-0.9%
|
$81,068
$13.86 P/Share
|
|
Mar 19
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
96,566
-12.19%
|
$1,255,358
$13.92 P/Share
|
|
Mar 19
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,672
-3.55%
|
$73,736
$13.92 P/Share
|
|
Mar 19
2024
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
27,603
-6.9%
|
$358,839
$13.92 P/Share
|
|
Feb 22
2024
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,821
-1.13%
|
$23,673
$13.08 P/Share
|
|
Feb 22
2024
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
1,821
-0.45%
|
$23,673
$13.08 P/Share
|
|
Feb 22
2024
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
7,706
-0.96%
|
$100,178
$13.08 P/Share
|
|
Feb 21
2024
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,115
+7.5%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.2M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 551K shares |
|---|---|
| Other acquisition or disposition | 139K shares |
| Exercise of conversion of derivative security | 331K shares |
| Open market or private purchase | 175K shares |
Sell / Disposition
2.49M
Shares
From
7
Insiders
| Open market or private sale | 2.49M shares |
|---|